Business Description
Royalty Pharma PLC
NAICS : 541714
SIC : 2833
ISIN : GB00BMVP7Y09
Share Class Description:
RPRX: Class ACompare
Compare
Traded in other countries / regions
RPRX.USARPRX.MexicoRPD.Germany IPO Date
2020-06-16Description
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.34 | |||||
Equity-to-Asset | 0.37 | |||||
Debt-to-Equity | 1.17 | |||||
Debt-to-EBITDA | 6.25 | |||||
Interest Coverage | 5.15 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 1.67 | |||||
Beneish M-Score | -3.37 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -11.6 | |||||
3-Year EBITDA Growth Rate | -14.5 | |||||
3-Year EPS without NRI Growth Rate | 30.7 | |||||
3-Year FCF Growth Rate | -2.9 | |||||
3-Year Book Growth Rate | 5.6 | |||||
Future 3-5Y EPS without NRI Growth Rate | 31.6 | |||||
Future 3-5Y Total Revenue Growth Rate | 10.29 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 80.31 | |||||
9-Day RSI | 67.98 | |||||
14-Day RSI | 62.23 | |||||
6-1 Month Momentum % | -8.02 | |||||
12-1 Month Momentum % | -4.7 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.35 | |||||
Quick Ratio | 9.35 | |||||
Cash Ratio | 9.26 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.89 | |||||
Dividend Payout Ratio | 0.75 | |||||
3-Year Dividend Growth Rate | 38.7 | |||||
Forward Dividend Yield % | 2.93 | |||||
5-Year Yield-on-Cost % | 2.93 | |||||
3-Year Average Share Buyback Ratio | -4.8 | |||||
Shareholder Yield % | 7.78 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | 42.91 | |||||
Net Margin % | 30.09 | |||||
FCF Margin % | 119.28 | |||||
ROE % | 10.54 | |||||
ROA % | 4.05 | |||||
ROIC % | 6.47 | |||||
ROCE % | 7.48 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 19.12 | |||||
Forward PE Ratio | 7.29 | |||||
PE Ratio without NRI | 26.15 | |||||
PS Ratio | 7.63 | |||||
PB Ratio | 1.99 | |||||
Price-to-Tangible-Book | 1.99 | |||||
Price-to-Free-Cash-Flow | 6.39 | |||||
Price-to-Operating-Cash-Flow | 6.39 | |||||
EV-to-EBIT | 14.66 | |||||
EV-to-Forward-EBIT | 9.76 | |||||
EV-to-EBITDA | 14.66 | |||||
EV-to-Forward-EBITDA | 9.76 | |||||
EV-to-Revenue | 7.97 | |||||
EV-to-Forward-Revenue | 6.95 | |||||
EV-to-FCF | 6.66 | |||||
Price-to-Graham-Number | 1.52 | |||||
Earnings Yield (Greenblatt) % | 6.82 | |||||
FCF Yield % | 20.76 | |||||
Forward Rate of Return (Yacktman) % | -16 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RPRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Royalty Pharma PLC Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 2,237.626 | ||
EPS (TTM) ($) | 1.5 | ||
Beta | 0.37 | ||
Volatility % | 18.42 | ||
14-Day RSI | 62.23 | ||
14-Day ATR ($) | 0.587425 | ||
20-Day SMA ($) | 27.457 | ||
12-1 Month Momentum % | -4.7 | ||
52-Week Range ($) | 25.2 - 31.655 | ||
Shares Outstanding (Mil) | 448.13 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Royalty Pharma PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Royalty Pharma PLC Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Royalty Pharma PLC Frequently Asked Questions
What is Royalty Pharma PLC(RPRX)'s stock price today?
The current price of RPRX is $28.70. The 52 week high of RPRX is $31.66 and 52 week low is $25.20.
When is next earnings date of Royalty Pharma PLC(RPRX)?
The next earnings date of Royalty Pharma PLC(RPRX) is 2024-11-08 Est..
Does Royalty Pharma PLC(RPRX) pay dividends? If so, how much?
The Dividend Yield %  of Royalty Pharma PLC(RPRX) is 2.89% (As of Today), Highest Dividend Payout Ratio of Royalty Pharma PLC(RPRX) was 0.75. The lowest was 0.33. And the median was 0.41. The  Forward Dividend Yield % of Royalty Pharma PLC(RPRX) is 2.93%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |